RxDoctor Payments Data

Laura O'Loughlin

Psychiatric/Mental Health · Milwaukee, WINPI 1588081913

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Johnson & Johnson at 45.5% of the total. Reporting peaked in 2024 at $1,264 and has fallen 68.4% since, to $399 in 2025.

$2,326in general payments, 2019–2025

Across 33 payments — averaging $70.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Axsome Therapeutics, Inc.$551
  • AbbVie$283
  • Abbott$155
  • Novo Nordisk$125
  • Boehringer Ingelheim$125
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$2,326100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,326 in reported general payments places this provider in the 85th percentile of 384 psychiatric/mental health providers in Wisconsin.

See all psychiatric/mental health providers in Wisconsin

Medicare billing

Part B allowed, 2024
$12,818
Medicare patients
95
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$16,620
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,447
Albuterol Sulfate HfaAlbuterol Sulfate53$1,276
Potassium Chloride29$963
Fluticasone Propionate50$891
Propranolol Hcl ErPropranolol Hcl13$888
Atorvastatin Calcium68$599
Gabapentin41$507
Losartan Potassium55$501
Levothyroxine Sodium43$453
Hydroxyzine Hcl57$447
Venlafaxine Hcl ErVenlafaxine Hcl13$393
Trazodone Hcl72$377
Omeprazole24$372
Duloxetine Hcl28$324

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →